Background illustration for clinical trials search

Paid Clinical Trials Joliet

Discover 2,355 paid clinical trials in Joliet, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,355

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

for

Non-small Cell Lung Cancer

Location: Orland Park IL, Warrenville IL, Oak Brook IL, Geneva IL,

Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 18+

Code: NCT06686771

Phase3, Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for

Locally Advanced Adrenal Cortical Carcinoma,

Location: Orland Park IL, Warrenville IL, Oak Brook IL, Geneva IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 12+

Code: NCT06900595

Phase2, Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Orland Park IL, Warrenville IL, Oak Brook IL,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for

Extensive Stage Lung Small Cell Carcinoma,

Location: Orland Park IL, Warrenville IL, Oak Brook IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06769126

Phase2, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Orland Park IL, Aurora IL, Warrenville IL, Oak Brook IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Orland Park IL, Warrenville IL, Oak Brook IL, Geneva IL,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06532279

Phase2, Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for

Biochemically Recurrent Prostate Carcinoma,

Location: Orland Park IL, Aurora IL, Lisle IL, Warrenville IL,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male

Age: 18+

Code: NCT04423211

Phase3, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Orland Park IL, Warrenville IL, Oak Brook IL, Hines IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT06031688

Phase2, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Orland Park IL, Palos Heights IL, Warrenville IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Orland Park IL, Palos Heights IL, Warrenville IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for

Metastatic Nasopharyngeal Carcinoma,

Location: Orland Park IL, Warrenville IL, Geneva IL, Chicago IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06029270

Phase2, Recruiting

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

for

Castration-Resistant Prostate Carcinoma,

Location: Orland Park IL, Warrenville IL, Geneva IL, Chicago IL,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT06470243

Phase3, Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Orland Park IL, Warrenville IL, Hazel Crest IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642572

Phase2, Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

for

Advanced Lung Non-Squamous Non-Small Cell Carcinoma,

Location: Orland Park IL, Aurora IL, Warrenville IL, Harvey IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04181060

Phase3, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for

Lung Non-Small Cell Carcinoma

Location: Orland Park IL, Palos Heights IL, Warrenville IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06116682

Phase2, Recruiting

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for

Hematopoietic and Lymphatic System Neoplasm,

Location: Orland Park IL, Warrenville IL, Oak Lawn IL, Geneva IL,

Sponsor: Children's Oncology Group

Sex: Female

Age: 0 - 39

Code: NCT06513962

Phase3, Recruiting

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

for

Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma

Location: Orland Park IL, Aurora IL, Warrenville IL, Yorkville IL,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT05647265

Phase2, Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

for

Psoriatic Arthritis

Location: Orland Park IL, Schaumburg IL, Lansing MI, Howell MI,

Sponsor: Takeda

Sex: All

Age: 18+

Code: NCT06671483

Phase3, Recruiting

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

for

Recurrent Glioblastoma, IDH-Wildtype,

Location: Orland Park IL, Chicago IL, Madison WI, Cincinnati OH,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05432804

Phase1, Phase2, Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for

Anatomic Stage II Breast Cancer AJCC v8,

Location: Orland Park IL, Downers Grove IL, Hazel Crest IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06058377

Phase3, Recruiting

Paid Clinical Trials Joliet

Filter results

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Interested in new trials?

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer